Table 2.

A list of clinical trials that identify the genetic modifiers, NF1 mutations, phenotypes, or gene therapies of NF1.

ClinicalTrials.gov ID	Study name	Recruitment status	Intervention	Phase
NCT01650142	Modifying Genes in Neurofibromatosis 1	Unknown	–	–
NCT04212351	Frameshift Peptides of Children with NF1	Recruiting	Genetic: frameshift array blood sample test	–
NCT02315625	Study of Mutation-Targeted Therapy with Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery	Completed	Sunitinib or everolimus	II
NCT02124772	Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations	Active, not recruiting	Trametinib or combination with dabrafenib	I/II
NCT02700230	Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery	Recruiting	Oncolytic measles virus encoding thyroidal sodium iodide symporter	I
NCT03872427	Testing Whether Cancers with Specific Mutations Respond Better to Glutaminase Inhibitor, CB-839 HCl, Anti-Cancer Treatment, BeGIN Study	Recruiting	Telaglenastat hydrochloride	II